dmitrii-guzhanin-istockphoto-com-scales--1

Dmitrii_Guzhanin / iStockphoto.com

15 November 2018Big Pharma

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing

21 February 2018 Infringement and plausibility were the biggest issues on the battleground in the UK Supreme Court’s hearing in a case dealing with second medical use patents, as Claire Phipps-Jones, Katie Cambrook and Rachel Mumby of Bristows report.

More on this story

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing

21 February 2018 Infringement and plausibility were the biggest issues on the battleground in the UK Supreme Court’s hearing in a case dealing with second medical use patents, as Claire Phipps-Jones, Katie Cambrook and Rachel Mumby of Bristows report.

More on this story

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing

21 February 2018 Infringement and plausibility were the biggest issues on the battleground in the UK Supreme Court’s hearing in a case dealing with second medical use patents, as Claire Phipps-Jones, Katie Cambrook and Rachel Mumby of Bristows report.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent